



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



NN1177 (trifluoroacetate salt)

Item No. 41333

MF: $C_{206}H_{323}N_{51}O_{66} \cdot XCF_3COOH$
FW: 4,570.1
Purity: $\geq 98\%$
Supplied as: A solid
Storage: $-20^\circ C$
Stability: ≥ 4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

NN1177 (trifluoroacetate salt) is supplied as a solid. A stock solution may be made by dissolving the NN1177 (trifluoroacetate salt) in the solvent of choice, which should be purged with an inert gas. NN1177 (trifluoroacetate salt) is sparingly soluble (1-10 mg/ml) in DMSO and slightly soluble (0.1-1 mg/ml) in acetonitrile and water.

Description

NN1177 is a dual peptide agonist of the glucagon receptor (GCGR) and glucagon-like peptide 1 receptor (GLP-1R).¹ It induces cAMP production in BHK-21 cells expressing human GCGR or GLP-1R ($EC_{50}s = 1.83$ and 0.92 pM, respectively). *In vivo*, NN1177 (3-5 nmol/kg) reduces body weight and cumulative food intake in a mouse model of diet-induced obesity. It also reduces body weight, hepatic fat accumulation and fibrosis, and plasma alanine transaminase (ALT) levels in a mouse model of non-alcoholic steatohepatitis (NASH) induced by a high-fat, high-fructose, and high-cholesterol diet.²

References

1. Simonsen, L., Lau, J., Kruse, T., *et al.* Preclinical evaluation of a protracted GLP-1/glucagon receptor co-agonist: Translational difficulties and pitfalls. *PLoS One* **17**(3), e0264974 (2022).
2. Monfeuga, T., Norlin, J., Bugge, A., *et al.* Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients. *Mol. Metab.* **79**, 101850 (2024).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 08/23/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM